Oncobiologics (OTLK) Expected to Announce Earnings on Friday

Oncobiologics (NASDAQ:OTLK) is expected to be releasing its Q4 2025 results before the market opens on Friday, December 26th. Analysts expect the company to announce earnings of ($0.23) per share and revenue of $5.8460 million for the quarter. Parties may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Wednesday, December 24, 2025 at 4:00 PM ET.

Oncobiologics Stock Performance

Shares of NASDAQ:OTLK opened at $2.07 on Friday. The business’s fifty day moving average price is $1.62 and its two-hundred day moving average price is $1.66. The stock has a market cap of $91.95 million, a PE ratio of -3.63 and a beta of 0.17. Oncobiologics has a one year low of $0.79 and a one year high of $3.39.

Institutional Investors Weigh In On Oncobiologics

Institutional investors have recently added to or reduced their stakes in the company. Russell Investments Group Ltd. grew its position in Oncobiologics by 865.2% in the second quarter. Russell Investments Group Ltd. now owns 24,477 shares of the company’s stock valued at $39,000 after acquiring an additional 21,941 shares in the last quarter. AQR Capital Management LLC boosted its stake in shares of Oncobiologics by 42.7% in the first quarter. AQR Capital Management LLC now owns 84,671 shares of the company’s stock valued at $103,000 after purchasing an additional 25,351 shares during the period. Finally, Goldman Sachs Group Inc. boosted its stake in shares of Oncobiologics by 74.1% in the first quarter. Goldman Sachs Group Inc. now owns 103,524 shares of the company’s stock valued at $126,000 after purchasing an additional 44,063 shares during the period. Hedge funds and other institutional investors own 11.20% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts recently commented on OTLK shares. Guggenheim cut Oncobiologics from a “buy” rating to a “neutral” rating in a research report on Thursday, August 28th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Oncobiologics in a report on Monday, December 8th. Zacks Research lowered shares of Oncobiologics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, August 27th. Chardan Capital restated a “neutral” rating and set a $3.00 target price on shares of Oncobiologics in a research report on Thursday, August 28th. Finally, Ascendiant Capital Markets cut their price target on Oncobiologics from $21.00 to $8.00 and set a “buy” rating for the company in a report on Monday, September 22nd. One equities research analyst has rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $6.50.

About Oncobiologics

Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.